PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies

@article{Pershadsingh2008PPARAP,
  title={PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies},
  author={Harrihar A. Pershadsingh and David M. Moore},
  journal={PPAR Research},
  year={2008},
  volume={2008},
  pages={115 - 170}
}
The angiogenic, neovascular proliferative retinopathies, proliferative diabetic retinopathy (PDR), and age-dependent macular degeneration (AMD) complicated by choroidal neovascularization (CNV), also termed exudative or "wet" AMD, are common causes of blindness. The antidiabetic thiazolidinediones (TZDs), rosiglitazone, and troglitazone are PPARgamma agonists with demonstrable antiproliferative, and anti-inflammatory effects, in vivo, were shown to ameliorate PDR and CNV in rodent models… CONTINUE READING
13 Citations
124 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 124 references

Similar Papers

Loading similar papers…